BML Raises Full-Year Earnings Forecast on New Customer Growth and Price Optimization

BML ( (JP:4694) ) has shared an update.

BML, Inc. has revised upward its consolidated earnings forecast for the fiscal year ending March 31, 2026, citing stronger-than-expected performance. The company now projects net sales of ¥149.0 billion, operating profit of ¥10.0 billion, ordinary profit of ¥10.5 billion, and profit attributable to owners of parent of ¥7.0 billion, all above the previous forecast and surpassing last year’s results, with basic earnings per share expected to rise to ¥183.88. Management attributes the improved outlook to steady acquisition of new customers and successful price optimization initiatives started in the prior fiscal year, which more than offset increased depreciation costs linked to new wings at the BML General Laboratory, signaling stronger profitability and operational leverage despite higher investment-related expenses.

The most recent analyst rating on (JP:4694) stock is a Hold with a Yen4233.00 price target. To see the full list of analyst forecasts on BML stock, see the JP:4694 Stock Forecast page.

More about BML

BML, Inc. is a Japan-based company listed on the Tokyo Stock Exchange Prime Market (securities code 4694), operating in the medical and diagnostic services sector, with its core activities centered on clinical testing and related laboratory services. The company’s operations are supported by large-scale facilities such as the BML General Laboratory, and it focuses on expanding its customer base while optimizing pricing for its services in the domestic healthcare market.

Average Trading Volume: 65,891

Technical Sentiment Signal: Buy

Current Market Cap: Yen148.6B

See more data about 4694 stock on TipRanks’ Stock Analysis page.